readthroughSign in
Jul 1, 2026Partnership

OneMedNet signs $25 million standby equity purchase deal with Yorkville

The agreement, dated July 1, 2026, lets OneMedNet sell shares to Yorkville over 36 months, subject to volume limits and an ownership cap.

OneMedNet Corporation entered into a standby equity purchase agreement on July 1, 2026 with YA II PN, Ltd., a Cayman Islands exempt limited partnership referred to as Yorkville. Under the agreement, the company has the option to sell to Yorkville up to $25 million of its common stock, at its request from time to time following the effectiveness of a resale registration statement covering those shares.1 The agreement terminates on its 36-month anniversary.1

Each individual advance is capped. An advance cannot exceed the greater of 500,000 shares or 100% of the average daily trading volume of common stock over the five trading days before the request.1 Shares would be purchased at 97% of the market price as defined in the agreement.1 The company may also set a minimum acceptable price for each advance, below which it would not be obligated to sell.1

There are additional limits on how much Yorkville can accumulate. Yorkville cannot purchase shares that would push its and its affiliates' ownership above 4.99% of outstanding voting power, and total shares issued under all advances cannot exceed 11,386,834 shares, representing 19.99% of the 56,952,652 shares outstanding as of June 30, 2026, unless shareholders approve issuances beyond that cap.1

The company also has registration obligations tied to this facility. OneMedNet agreed to file a resale registration statement covering the shares issuable under the agreement, and it may not request advances until that registration statement is effective.1

The agreement was filed as an exhibit to the 8-K, and the filing was signed by CEO Aaron Green. The full description of the agreement in the filing is qualified by the actual agreement text, filed as Exhibit 10.1.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.